Many studies show that patients often struggle to interpret numerical information in medical contexts, especially probabilities related to recovery and side effects. In a recently published Letter in ...

168 people finished in under a minute. We created a crossword puzzle just for Californians. 248 people are playing right now. Catch the 49ers take on the Seahawks on Saturday, January 17. Here’s ...

After starting as a production assistant, "Trapper" Dave Calabrese filled in for other DJs at WPLR and had his own show on Saturdays. "I’ll meet you in the music. Come find me anytime," said ...

At first glance, the image looks like black and grey television static. The image is filled with tiny specks of light and dark so densely that your eyes may not know where to focus. But mind you, this ...

Did anyone win the Mega Millions drawing Jan. 2? The winning numbers for the Friday, Jan. 2, Mega Millions drawing were: 6, 13, 34, 43 and 52 and the Mega Ball was 4. No one picked all six numbers, ...

We may receive a commission on purchases made from links. Oscillating multi-tools can be an invaluable part of your toolkit, not least because they can be used for so many different applications.

A single ticket sold in New Jersey won the $90 million Mega Millions jackpot on Tuesday, Dec. 2, 2025. The winning numbers for the drawing were 17, 25, 26, 53, 60, and the Mega Ball was 16. Following ...

Player can pick six numbers from two separate pools of numbers — five different numbers from 1 to 70 (the white balls) and one number from 1 to 24 (the gold Mega Mall). Players can also select the ...

The Mega Millions jackpot rose to $90 million for the drawing on Tuesday, Dec. 2, after no one matched all the winning numbers in the drawing on Friday, Nov. 28. On Tuesday, someone from New Jersey ...

Washington's defense was so bad that head coach Dan Quinn finally took over defensive play-calling from defensive coordinator Joe Whitt Jr. ahead of Week 11. While Whitt had his issues, he was far ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...